Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MYX001
MIFTS: 46

Myxopapillary Ependymoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Myxopapillary Ependymoma

About this section

MalaCards integrated aliases for Myxopapillary Ependymoma:

Name: Myxopapillary Ependymoma 12 52 58 15 71
Ependymoma Myxopapillary 54

Characteristics:

Orphanet epidemiological data:

58
myxopapillary ependymoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adolescent,All ages,Childhood;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:5075
MeSH 43 D004806
NCIt 49 C3697
SNOMED-CT 67 1623000
ICD10 via Orphanet 33 D43.2
UMLS via Orphanet 72 C0205769
Orphanet 58 ORPHA251643
UMLS 71 C0205769
Sources

Summaries for Myxopapillary Ependymoma

About this section
NIH Rare Diseases : 52 Myxopapillary ependymoma (MEPN) is a slow-growing ependymoma (a type of glioma, which is a tumor that arises from the supportive tissue of the brain and spinal cord). They tend to occur in the lower part of the spinal column and are usually considered to be benign, low-grade or grade I tumors. The age of diagnosis ranges from 6 to 82 years. Symptoms of an ependymoma are related to the location and size of the tumor and may include nausea, vomiting, headache, pain, numbness, bowel or bladder symptoms, and various other signs and symptoms. The cause of ependymomas is unknown. They are known to recur locally (more commonly in individuals diagnosed in childhood). Treatment may vary depending on the location, grade , and whether the tumor has spread to the spine, but typically includes aggressive surgery. Management may also include chemotherapy and radiation therapy .

MalaCards based summary : Myxopapillary Ependymoma, also known as ependymoma myxopapillary, is related to benign ependymoma and cellular ependymoma, and has symptoms including back pain An important gene associated with Myxopapillary Ependymoma is GFAP (Glial Fibrillary Acidic Protein), and among its related pathways/superpathways are Neuroscience and Spinal Cord Injury. The drugs Donepezil and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and skin, and related phenotypes are ependymoma and abnormal conus terminalis morphology

Sources

Related Diseases for Myxopapillary Ependymoma

About this section

Diseases related to Myxopapillary Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 298)
# Related Disease Score Top Affiliating Genes
1 benign ependymoma 32.6 VIM SYP S100B NF2 MUC1 GFAP
2 cellular ependymoma 32.1 SYP RELA C11orf95
3 spinal meningioma 30.9 SMARCB1 NF2
4 adenoid cystic carcinoma 30.9 VIM S100B NCAM1 MUC1
5 secretory meningioma 30.6 VIM SMARCB1 NF2 MUC1
6 subependymoma 30.6 SYP NCAM1 GFAP
7 chordoma 30.5 VIM SMARCB1 S100B NCAM1 MUC1 GFAP
8 leukoencephalopathy, hereditary diffuse, with spheroids 30.5 SYP S100B GFAP
9 teratoma 30.4 VIM SYP SMARCB1 GFAP
10 paraganglioma 30.3 SYP S100B NCAM1 GFAP
11 juvenile pilocytic astrocytoma 30.3 SYP S100B LUC7L2 GFAP
12 neurofibroma 29.9 VIM SYP S100B NF2 MUC1
13 hydrocephalus 29.9 VIM SYP SMARCB1 S100B GFAP
14 meningioma, familial 29.7 SYP SMARCB1 NF2 MN1 GFAP
15 neurilemmoma 29.6 VIM SMARCB1 S100B NF2 MUC1 GFAP
16 meningioma, radiation-induced 29.5 VIM SMARCB1 S100B NF2 MUC1 MN1
17 chordoid meningioma 29.5 VIM SYP S100B NF2 NCAM1 MUC1
18 anaplastic ependymoma 29.3 VIM SYP S100B RELA NF2 MUC1
19 spinal cord ependymoma 28.5 YAP1 RELA NF2 LUC7L2 HOXB13 CTU1
20 rare tumor 10.7
21 back pain 10.7
22 sclerosing perineurioma 10.6 S100B MUC1
23 localized hypertrophic neuropathy 10.6 S100B MUC1
24 reticular perineurioma 10.6 S100B MUC1
25 aggressive digital papillary adenocarcinoma 10.5 S100B MUC1
26 primitive neuroectodermal tumor of the cervix uteri 10.5 VIM GFAP
27 non-functioning pituitary adenoma 10.5 S100B MUC1
28 hydromyelia 10.5 VIM S100B
29 meningeal melanocytoma 10.5 S100B MUC1
30 bednar tumor 10.5 VIM S100B
31 nodular hidradenoma 10.5 VIM MUC1
32 endometrial mucinous adenocarcinoma 10.5 VIM MUC1
33 cauda equina syndrome 10.5
34 lymphoplasmacyte-rich meningioma 10.5
35 biliary tract benign neoplasm 10.5 NCAM1 MUC1
36 solid adenocarcinoma with mucin production 10.5 NCAM1 MUC1
37 suprasellar meningioma 10.5 NF2 GFAP
38 malignant peritoneal mesothelioma 10.5 NF2 MUC1
39 chondroid chordoma 10.5 VIM MUC1
40 odontogenic myxoma 10.5 VIM S100B
41 reticulum cell sarcoma 10.4 VIM MUC1
42 desmoplastic small round cell tumor 10.4 VIM MUC1
43 scoliosis 10.4
44 siderosis 10.4
45 mucinous adenocarcinoma 10.4
46 appendix adenocarcinoma 10.4
47 glial tumor 10.4
48 gemistocytic astrocytoma 10.4 S100B GFAP
49 myopericytoma 10.4 S100B RELA
50 pericardial mesothelioma 10.4 VIM MUC1

Graphical network of the top 20 diseases related to Myxopapillary Ependymoma:



Diseases related to Myxopapillary Ependymoma
Sources

Symptoms & Phenotypes for Myxopapillary Ependymoma

About this section

Human phenotypes related to Myxopapillary Ependymoma:

58 31 (show all 12)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ependymoma 58 31 obligate (100%) Obligate (100%) HP:0002888
2 abnormal conus terminalis morphology 58 31 hallmark (90%) Very frequent (99-80%) HP:0031938
3 vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002013
4 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
5 unsteady gait 58 31 frequent (33%) Frequent (79-30%) HP:0002317
6 neck pain 58 31 frequent (33%) Frequent (79-30%) HP:0030833
7 autonomic bladder dysfunction 58 31 frequent (33%) Frequent (79-30%) HP:0005341
8 abnormal large intestine physiology 58 31 frequent (33%) Frequent (79-30%) HP:0012700
9 neoplasm of the skin 58 31 occasional (7.5%) Occasional (29-5%) HP:0008069
10 abnormal sacrum morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0005107
11 abnormality of the auditory canal 58 31 very rare (1%) Very rare (<4-1%) HP:0000372
12 neoplasm of the central nervous system 58 Frequent (79-30%)

UMLS symptoms related to Myxopapillary Ependymoma:


back pain

GenomeRNAi Phenotypes related to Myxopapillary Ependymoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 SMARCB1

MGI Mouse Phenotypes related to Myxopapillary Ependymoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.32 CA2 GFAP HOXB13 NCAM1 NF2 RELA
Sources

Drugs & Therapeutics for Myxopapillary Ependymoma

About this section

Drugs for Myxopapillary Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 119)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Donepezil Approved Phase 3 120014-06-4 3152
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
4
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
5 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
6 Cholinesterase Inhibitors Phase 3
7 Cholinergic Agents Phase 3
8 Liver Extracts Phase 3
9 Cola Phase 3
10 Anesthetics Phase 3
11 Narcotics Phase 3
12 Analgesics Phase 3
13 Analgesics, Opioid Phase 3
14 Anesthetics, General Phase 3
15 Anesthetics, Intravenous Phase 3
16 Neurotransmitter Agents Phase 3
17 Central Nervous System Stimulants Phase 3
18 Dopamine Agents Phase 3
19 Dexmethylphenidate Hydrochloride Phase 3
20
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
21
Etoposide Approved Phase 2 33419-42-0 36462
22
Sodium citrate Approved, Investigational Phase 2 68-04-2
23
Tamoxifen Approved Phase 2 10540-29-1 2733526
24
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
25
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
26
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
27
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
28
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
29
leucovorin Approved Phase 2 58-05-9 6006 143
30
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
31
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
32
Iodine Approved, Investigational Phase 2 7553-56-2 807
33
Promethazine Approved, Investigational Phase 2 60-87-7 4927
34
Acetaminophen Approved Phase 2 103-90-2 1983
35
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
36
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
37
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
38
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
39
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
40 Etoposide phosphate Phase 2
41 Hormones Phase 2
42 Antineoplastic Agents, Hormonal Phase 2
43 Estrogen Antagonists Phase 2
44 Hormone Antagonists Phase 2
45 Citrate Phase 2
46 Estrogen Receptor Modulators Phase 2
47 topoisomerase I inhibitors Phase 2
48 Estrogens Phase 2
49 Estrogen Receptor Antagonists Phase 2
50 Vitamin B Complex Phase 2

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
2 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
4 A PHASE II TRIAL OF ETOPOSIDE AND CISPLATIN IN THE TREATMENT OF RECURRENT EPENDYMOMAS Completed NCT00002876 Phase 2 cisplatin;etoposide
5 A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
6 PHASE I STUDY OF ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT BRAIN TUMORS Completed NCT00002752 Phase 1, Phase 2
7 Improved Characterization of Brain Tumors By MRI and MRS Completed NCT00274755 Phase 2 chemotherapy
8 A Pilot Study of Tamoxifen, Carboplatin and Topotecan in the Treatment of Recurrent or Refractory Primary Brain or Spinal Cord Tumors or Metastatic Epithelial Cancers With Central Nervous System Metastases Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
9 A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue Completed NCT01032200 Phase 2 Armodafinil
10 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
11 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
12 Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases Completed NCT00070161 Phase 2 donepezil hydrochloride
13 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
14 Defining Functional Tissue in Brain Tumors With Integrated Neuroimaging (Pilot Study) Withdrawn NCT00005083 Phase 2
15 Phase I Study Of SCH66336 (Lonafarnib), A Farnesyl Protein Transferase Inhibitor In Combination With Temozolomide In Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
16 Determination of the In-Tumor-Concentration of Imatinib Mesylate in Malignant Glioma After Oral Administration Completed NCT00401024 Phase 1 imatinib mesylate
17 PROTOCOL FOR A PHASE I STUDY OF INTRACYSTIC ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 IN THE TREATMENT OF PATIENTS WITH RECURRENT CYSTIC GLIOMAS Completed NCT00002753 Phase 1
18 A Phase I Trial Of A Thalidomide Analog, CC-5013, For The Treatment Of Patients With Recurrent High-Grade Gliomas Completed NCT00036894 Phase 1 lenalidomide
19 Phase I Study of Intrathecal 131-I-3F8 Monoclonal Antibody in Patients With GD2 Positive Leptomeningeal Neoplasms Completed NCT00003022 Phase 1
20 A Phase I Study Of Vaccination With Telomerase Peptide Plus GM-CSF Completed NCT00069940 Phase 1
21 A Pilot Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
22 A Phase I Study of Bortezomib and Temozolomide in Patients With Refractory Solid Tumors Completed NCT00544284 Phase 1 bortezomib;temozolomide
23 A Phase I Trial of Subcutaneous And/Or Oral Calcitriol [(1,25-COH)2D3] and Carboplatin in Advanced Solid Tumors Completed NCT00008086 Phase 1 carboplatin
24 Pilot Feasibility and Safety Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Genetically-Modified Autologous CD8+ T Cell Clones Completed NCT00730613 Phase 1
25 Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b Followed by Cisplatin, Vinblastine and Dacarbazine for Patients With Melanoma or Malignancies Potentially Responsive to SSG and/or Interferons Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
26 A Phase I, Open-Label, Maximum Tolerated Single-Cycle and Four-Cycle Dose-Finding Study to Evaluation the Safety and Tolerability of 90Y-SMT 487 Administered by Intravenous Infusion to Subjects With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00006368 Phase 1
27 A PHASE I STUDY OF THE COMBINATION OF CAI AND PACLITAXEL IN ADULT PATIENTS WITH REFRACTORY CANCERS OR LYMPHOMA Completed NCT00019019 Phase 1 carboxyamidotriazole;paclitaxel
28 Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Therapeutic Principles Completed NCT00049296 Phase 1 docetaxel;thalidomide
29 A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas Completed NCT00020579 Phase 1 entinostat
30 Mutant MGMT Gene Transfer Into Human Hematopoietic Progenitors to Protect Hematopoiesis During O6-Benzylguanine (BG, NSC 637037) and Carmustine Followed by Temozolomide Therapy of Advanced Solid Tumors Terminated NCT00003567 Phase 1 O6-benzylguanine;carmustine;temozolomide
31 Identification of Genes Involved in the Pathogenesis of Gliomas by Transcriptome Analysis Completed NCT00967200
32 Magnetic Resonance Correlates of Glioma Tumor Burden Completed NCT00005082
33 Prospective Study on the Short-Term Adverse Effects From Gamma Knife Radiosurgery Completed NCT00255671
34 Temozolomide Induced Changes in Semen/Sperm Analysis in Men With Newly Diagnosed, Progressive or Recurrent Primary Malignant Brain Tumors Completed NCT00499798
35 San Francisco Bay Area Adult Glioma Prognosis Study Protocol Completed NCT01009307
36 Exploring Outcomes and Risk in Patients With Rare Central Nervous System Tumors Recruiting NCT03251989
37 Perfusion Magnetic Resonance Imaging of Brain Tumors: Correlation With Indicators of Angiogenesis Withdrawn NCT00005790

Search NIH Clinical Center for Myxopapillary Ependymoma

Sources

Genetic Tests for Myxopapillary Ependymoma

About this section
Sources

Anatomical Context for Myxopapillary Ependymoma

About this section

MalaCards organs/tissues related to Myxopapillary Ependymoma:

40
Brain, Spinal Cord, Skin, Liver, T Cells, Temporal Lobe, Bone
Sources

Publications for Myxopapillary Ependymoma

About this section

Articles related to Myxopapillary Ependymoma:

(show top 50) (show all 341)
# Title Authors PMID Year
1
Immunohistochemical comparison of chordoma with chondrosarcoma, myxopapillary ependymoma, and chordoid meningioma. 54 61
19521276 2009
2
An immunohistochemical comparison of chordoma with renal cell carcinoma, colorectal adenocarcinoma, and myxopapillary ependymoma: a potential diagnostic dilemma in the diminutive biopsy. 61 54
7504258 1993
3
Diagnosis: Subcutaneous myxopapillary ependymoma. 61
32147755 2020
4
Diagnosis: subcutaneous myxopapillary ependymoma. 61
32172345 2020
5
Intramedullary Masses of the Spinal Cord: Radiologic-Pathologic Correlation. 61
32530746 2020
6
cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. 61
32502305 2020
7
Analyzing the role of adjuvant or salvage radiotherapy for spinal myxopapillary ependymomas. 61
32357340 2020
8
Mobile Myxopapillary Ependymoma with Associated Filum Terminale Cyst. 61
32339736 2020
9
Long-Term Surgical Resection Outcomes of Pediatric Myxopapillary Ependymoma: Experience of Two Centers and Brief Literature Review. 61
31899399 2020
10
Resection of Myxopapillary Ependymoma of the Filum Terminale: 2-Dimensional Operative Video. 61
31073602 2020
11
Molecular characterization of histopathological ependymoma variants. 61
31679042 2020
12
Myxopapillary ependymoma of the sacrum. 61
31555979 2020
13
Reports of a Conus Cauda Tumor with Holocord Syrinx in an Adolescent Girl. 61
32435308 2020
14
Filum Terminale Ependymoma in an Infant with Meningocele. 61
31962322 2020
15
Subcutaneous sacrococcygeal myxopapillary ependymoma misdiagnosed as pilonidal disease. 61
31900294 2020
16
Long-term survival of a sacro-coccygeal myxopapillary ependymoma with extra-neural metastases: case report and review of the literature. 61
31989347 2020
17
TERTp Mutation Detection in Plasma by Droplet-Digital Polymerase Chain Reaction in Spinal Myxopapillary Ependymoma with Lung Metastases. 61
31330336 2019
18
Spinal Myxopapillary Ependymoma: The Sapienza University Experience and Comprehensive Literature Review Concerning the Clinical Course of 1602 Patients. 61
31152881 2019
19
Myxopapillary ependymoma of cauda equina presented with communicating hydrocephalus and papilloedema: A case report. 61
31424046 2019
20
[Superficial siderosis of the central nervous system caused by myxopapillary ependymoma of conus medullaris and cauda equine: a case report and literature review]. 61
31420638 2019
21
Clinical characteristics and surgical outcomes of spinal myxopapillary ependymomas. 61
31473875 2019
22
Management and Outcome Analysis of Conus and Filum ependymoma: A Tertiary Center Study. 61
31497108 2019
23
Benign ependymoma with extensive intracranial and spinal cerebrospinal fluid dissemination: case report and literature review. 61
28633540 2019
24
Invasive myxopapillary ependymoma of the lumbar spine: A case report. 61
31183345 2019
25
Myxopapillary Ependymoma. 61
30844350 2019
26
Intradural Extramedullary Spinal Neoplasms: Radiologic-Pathologic Correlation. 61
30844353 2019
27
Recurrent Extradural Myxopapillary Ependymoma With Oligometastatic Spread. 61
31850213 2019
28
A rare case of an intramedullary metastasis of a myxopapillary ependymoma. 61
31528421 2019
29
Natural Course of Myxopapillary Ependymoma: Unusual Case Report and Review of Literature. 61
30321682 2019
30
DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. 61
30053291 2018
31
Isolated myxopapillary ependymoma of the fourth ventricle: case report and review of literature. 61
30317890 2018
32
Pediatric extraspinal sacrococcygeal ependymoma (ESE): an Italian AIEOP experience of six cases and literature review. 61
29725826 2018
33
Remarkable efficacy of temozolomide for relapsed spinal myxopapillary ependymoma with multiple recurrence and cerebrospinal dissemination: a case report and literature review. 61
29270703 2018
34
Myxopapillary Ependymoma of Lumbar Soft Tissue: A Case Report With Gene Expression Evaluation. 61
29254456 2018
35
Unique combination of myxopapillary ependymoma and conus lipoma with subcutaneous extension in an 11-month-old child. 61
29380114 2018
36
Unusual paediatric spinal myxopapillary ependymomas: Unique molecular entities or pathological variations on a theme? 61
29402569 2018
37
[Presacral lesion at the rima ani]. 61
29018939 2018
38
Teaching Case 2-2018: Sclerosing myxopapillary ependymoma mimicking whorling-sclerosing meningioma. 61
29436365 2018
39
Metastases of spinal myxopapillary ependymoma: unique characteristics and clinical management. 61
29219779 2018
40
Myxopapillary ependymoma with anaplastic features: A case report with review of the literature. 61
30294495 2018
41
An Extremely Rare Case of Back and Hip Pain due to the Metastasis of Late Recurrent Myxopapillary Ependymoma to the Inguinal Lymph Node. 61
29166763 2018
42
Unusual cauda equina syndrome due to multifocal ependymoma infiltrated by lymphoma. 61
29354750 2017
43
Sporadic NF2 Mosaic: Multiple spinal schwannomas presenting with severe, intractable pain following pregnancy. 61
29780700 2017
44
Spinal myxopapillary ependymoma presenting with low back pain and subarachnoid hemorrhage. 61
28737370 2017
45
Occipital Intraparenchymal Myxopapillary Ependymoma: Case Report and Literature Review. 61
29114296 2017
46
You're the Flight Surgeon. 61
28923150 2017
47
Characterization of gliomas: from morphology to molecules. 61
28674742 2017
48
Anaplastic myxopapillary ependymoma in an infant: Case report and literature review. 61
28580214 2017
49
Primary Seeding of Myxopapillary Ependymoma: Different Disease in Adult Population? Case Report and Review of Literature. 61
28040529 2017
50
Solitary aneurysm of the filum terminale artery: A case report and review of the literature. 61
28868191 2017
Sources

Variations for Myxopapillary Ependymoma

About this section
Sources

Expression for Myxopapillary Ependymoma

About this section
Search GEO for disease gene expression data for Myxopapillary Ependymoma.
Sources

Pathways for Myxopapillary Ependymoma

About this section

Pathways related to Myxopapillary Ependymoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
11.97 SYP S100B NF2 NCAM1 GFAP CA2
2
Spinal Cord Injury 1
11.51 VIM PLA2G5 GFAP
3
Signaling by ERBB4 65
Show member pathways
 11.37 YAP1 S100B GFAP
4
Neural Stem Cells and Lineage-specific Markers 64
10.92 VIM SYP S100B NCAM1 GFAP
Sources

GO Terms for Myxopapillary Ependymoma

About this section

Biological processes related to Myxopapillary Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament organization GO:0045109 9.37 VIM GFAP
2 astrocyte development GO:0014002 9.32 VIM GFAP
3 Bergmann glial cell differentiation GO:0060020 9.26 VIM GFAP
4 regulation of stem cell proliferation GO:0072091 9.16 YAP1 NF2
5 positive regulation of histone H4 acetylation GO:0090240 8.96 SMARCB1 MUC1
6 intermediate filament-based process GO:0045103 8.62 VIM GFAP
Sources

Sources for Myxopapillary Ependymoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....